Background
==========

Tumor-associated macrophages (TAMs) are the most abundant cancer stromal cells involved in the host immune system \[[@B1],[@B2]\]. In recent years, increasing attention has focused on TAMs, unique macrophage populations that play pivotal roles in tumor immunosuppression, and provide a suitable microenvironment for cancer development and progression\[[@B3]\]. TAM infiltration has been found to be correlated with a worse outcome in several malignant tumors \[[@B4]-[@B9]\]. The possible mechanism by which TAMs support tumor progression and help the tumor evade immunosurveillance is through the release a spectrum of tumor promoting and immunosuppressive products.

*Interleukin-10(IL-10)*, *cathepsin B*or *cathepsin S*was reported to be closely associated with TAMs in recent literatures \[[@B10]-[@B12]\]. *IL-10*is produced primarily by T cells, B cells, dendritic cells, and monocytes/macrophages\[[@B13]\]. Tumor-associated macrophages form a major component in a tumor, and have been suggested to play an essential role in the complex process of tumor-microenvironment coevolution and tumorigenesis\[[@B1]\]. Previous reports have also shown that TAMs produce high levels of *IL-10*, exhibit little cytotoxicity for tumor cells\[[@B14]\]. However, there are controversies regarding its role in the progression of cancer \[[@B15],[@B16]\]. So it is important to isolate TAM from tumor cells to study the role of *IL-10*in the progress of cancer.

By using DNA-microarray technology, recent study demonstrated that NSCLC patients with a high expression level of cathepsins in lung cancer tissue (both tumor cells and stroma cells) had a poor outcome \[[@B17]\]. Interestingly, it has been shown that TAM is the primary source of high levels of cathepsin activity in pancreatic, breast and prostate cancer animal models \[[@B10]-[@B12]\]. However, the significance of cathepsins expressed by TAM in NSCLC remains unknown.

In the present study, we assessed *IL-10, cathepsin B and cathepsin S*expression in TAMs, freshly isolated from lung tumor tissue, in correlation with clinicopathological factors in NSCLC.

Materials and methods
=====================

Subject characteristics
-----------------------

63 paired peripheral blood samples and primary lung cancer tissues were collected from patients before or at the time of surgical resection at the Center for Lung Cancer Prevention and Treatment of Shanghai Cancer Hospital from June 2009 to March 2010. Data collected included age, sex, smoking history, histopathological diagnosis, TNM stage, lymphovascular invasion, pleural invasion, and tumor differentiation. Histological diagnoses, presence of lymphovascular invasion(LVI), and grade of differentiation were confirmed by two senior histopathologists. A consent form was signed by every patient or his/her legal representatives. This study was approved by the committees for Ethical Review of Research at Shanghai Cancer Hospital.

Histological diagnosis and grade of differentiation were determined in accordance with the World Health Organization criteria for lung cancer\[[@B18]\]. The pathologic tumor stage (p stage) was determined according to the revised TNM classification of lung cancer\[[@B19]\].

Isolation of tumor-associated macrophages
-----------------------------------------

TAMs were isolated from solid tumors according to literature reports \[[@B20]-[@B22]\]. Briefly, Tumor tissue was cut into 2 mm fragments, followed by collagenase digestion (0.3 mg/ml, Worthington Biochemical Corp, NJ, USA) for 1 h at 37°C. The suspension was filtered through a 70 μm stainless steel wire mesh to generate a single-cell suspension. The suspension was centrifuged and washed twice with PBS. Cells were left to adhere in serum-free RPMI 1640 for 40 min. Nonadherent cells were washed away. Ninety-five percent of the remaining adherent cells were TAMs as assessed by morphology and macrophage specific marker CD68 positivity.

### Immunofluorescence

TAMs were adhered to 24-well plate , fixed in 4% paraformaldehyde at room temperature for 5 minutes, washed with PBS twice, incubated with 1% BSA at 37°C for 30 minutes to block nonspecific interactions, and then stained with primary antibodies to CD68 (1:100 dilution, sc-20060, Santa Cruz Biotechnology, CA, USA) at 4°C overnight. After several washes with PBS, the cells were incubated in an appropriate, rhodamine-labeled goat anti-mouse secondary antibody(Proteintech Group, Inc, Chicago ,USA) at room temperature for 1 h. Nuclei of all cells were then stained with 4\'6-diamidino-2-phenylindole(DAPI). Image was taken at 200 × magnification on an Olympus-IX51 microscope. For each patient, 10 fields were imaged and measured for percentage of macrophage (CD68 positive cells/DAPI stained cells). Immunofluorescence was repeated in three randomly selected patients.

Preparation normal macrophage
-----------------------------

Macrophage (Mφ) was obtained as described previously \[[@B20]\]. In brief, the mononuclear cells were isolated from peripheral blood matched with TAMs by Ficoll-Hypaque density gradient centrifugation (density, 1.077 ± 0.001 g/ml, Axis-Shield, Oslo, Norway) at 450 × g for 30 min at room temperature. The mononuclear cells were washed thrice with PBS and plated at 1 × 10^7^in 6-cm tissue culture dishe for 2 h in DMEM alone. Thereafter, the nonadherent cells were washed thrice with warm PBS and the adherent monocytes were cultured in DMEM containing 5% FBS and 25 ng/ml human macrophage colony-stimulating factor((rhM-CSF, PeproTech, Rocky Hill, NJ, USA), The medium was changed every 2 days, and macrophage were obtained after 6 days in vitro cultivation.

RNA isolation and Quantitative real-time RT-PCR(QRT-PCR)
--------------------------------------------------------

Total RNA was isolated from TAMs and their matched macrophages by using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) as described by the manufacturer\'s protocol. For mRNA analysis, an aliquot containing 2 μg of total RNA was transcribed reversely using M-MLV reverse transcriptase (Promega, Madison, WI, USA). Specific primers (Genery, Shanghai, China) were used to amplify cDNA. QRT-PCR was done using SYBR Green PCR master mix (Applied Biosystems, Piscataway, NJ, USA). The primers for QRT-PCR were: *β-actin*forward (F) 5\' ACCACA CCTTCTACAATGA3\'*, β-actin*reverse(R) 5\'GTCATCTTCTCGCGGTTG3\'; *IL-10*F 5\' AGAACCT GAAGACCCTCAGGC3\', *IL-10*R 5\' CCACGGCCTTGCTCTTGTT 3\'; *cathepsin B*F 5\' TGCA GCGCTGGGTGGATCTA 3\'; *cathepsin B*R 5\' ATTGGCCAACACCAGCAGGC 3\'; *cathepsin S*F 5\' GCTTCTCTTGGT GTCCATAC 3\', *cathepsin S*R 5\' CATTACTGCGGGAATGAGAC 3\'. The amplification protocol consisted of an initial 10 min denaturation step at 95°C, followed by 40 cycles of PCR at 95°C for 15s, 60°C for 1 min and detection by the ABI-Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Each sample was assayed in triplicate. The comparative C~T~method (ΔΔC~T~method) was used to determine the quantity of the target sequences in TAM relative both to Mφ (calibrator) and to β-actin (an endogenous control). Relative expression levels were presented as the relative fold change and calculated using the formula: 2 ^-ΔΔCT^= 2-(ΔC~T~^(TAM)^- ΔC~T~^(^Mφ^)^where each ΔC~T~=ΔC~T~^target^-ΔC~T~^β-actin^.

Immunohistochemistry
--------------------

For exact identification of IL-10 or cathepsin B expression in TAMs, serial sections were used to examine the expression of IL-10, cathepsin B in TAMs. Samples were fixed in 4% formaldehyde in PBS (pH 7.2) and paraffin embedded. 4-μm thickness was cut from each paraffin block. After dewaxing and rehydration, the sections were microwaved for antigen retrieval in 10 mmol/liter citrate buffer (pH 6.0) for 10 min, and then allowed to cool for 1 hour at room temperature. Endogenous peroxidase activity was blocked with hydrogen peroxide; Nonspecific binding was blocked by preincubation with 10% goat serum in PBS for 30 minutes at room temperature. Slides were incubated with the primary antibodies directed against monoclonal anti-human CD68 antibody (1:200 dilution, sc-20060, Santa Cruz, CA, USA), monoclonal anti-human IL-10 antibody (1:100 dilution, BA1201,Boster, WuHan, China) or polyclonal anti-human cathepsin B antibody (1:100 dilution, ab49232, Abcam, MA, USA). The results were visualized using the streptavidine-biotin immunoperoxidase detection kit and AEC chromogen (Maixin Bio, FuZhou, China) based on the manufacturer\'s instruction. Positive cells stained red. The negative control involved omission of the primary antibody.

Statistical analysis
--------------------

Statistical analysis software (Prism 5.0, GraphPad Software Inc, La Jolla, CA, USA and SPSS Version 13.0 software, SPSS Inc, Chicago, IL, USA) was used to perform the analyses. Data are expressed as median (range). The Mann-Whitney test was used for the comparison between TAM and normal macrophage. The correlation between *IL-10*or *cathepsin B*expression and clinicopathologic factors was analyzed by Mann-Whitney test. Multivariate logistic regression was performed to evaluate the relationships between the pathological stage (with early and late stage as dependent variables) and covariates (age, sex, tobacco use, tumor histology and *IL-10*expression in TAMs). For this analysis, the median value of *IL-10*was chosen as the cut-off point for dividing the patients into the two groups. Two-tailed P value less than 0.05 was considered statistically significant.

Results
=======

Patients characteristics
------------------------

The patient characteristics are described in Table [1](#T1){ref-type="table"}. Patients (40 males and 23 females) had a mean age of 58.8 ± 1.1 years. Fifty-four patients had a smoking history, and forty-six were non-smokers. Adenocarcinoma was the most common tumor type (54%) followed by squamous cell carcinoma (32%). 30 patients (48%) were stage I (early stage), and the remaining 34 patients were (52%) stages II, III or IV (late stage) of the disease.

###### 

characteristics for the patients included in this study

  characteristic                                         **No.**^**a**^**(N= 63)**   \%
  ---------------------------- ------------------------- --------------------------- ------
  Age/years(Median,range)                                58 (37-76)                  
  Sex                                                                                
                               Male                      40                          63.5
                               Female                    23                          36.5
  Tobacco use                                                                        
                               Current                   22                          35
                               Former                    12                          19
                               Never                     29                          46
  Histology                                                                          
                               Adenocarcinoma            34                          54
                               Squamous cell carcinoma   20                          32
                               Others^b^                 9                           14
  Stage                                                                              
                               StageⅠ                    30                          48
                               StageⅡ                    11                          17
                               StageⅢ                    17                          27
                               StageⅣ^c^                 5                           8
  Lymph node metastasis                                                              
                               N0                        42                          67
                               N1/N2                     21                          33
  Pleural invasion                                                                   
                               Negative                  43                          68
                               Positive                  20                          32
  Lymphovascular invasion                                                            
                               Negative                  51                          81
                               Positive                  12                          9
  Histologic differentiation                                                         
                               Well/Moderate             30                          48
                               Poor                      26                          41
                               not available^d^          7                           11

^a^Number for all except age.

^b^Include 2 Large cell carcinoma, 2 Carcinoid, 1 malignant clear cell sugar tumor, 1 Sarcomatoid carcinoma, and 3 malignancy , but type undetermined.

^c^Stage IV was found incidentally during the operation or only for biopsy

^d^Include Carcinoid, malignant clear cell sugar tumor, Sarcomatoid carcinoma, multiple primary lung cancer.

Isolation and identification of tumor-associated macrophages
------------------------------------------------------------

In our study, 71 NSCLC samples were collected and TAMs were successful isolated from all samples. However, cell number of TAMs isolated from 8 NSCLC was inadequate for gene expression analysis, and excluded from this study. So TAMs from 63 NSCLC were finally analyzed. The successful rate was 89%(63/71). Each sample weight ranged from 10 mg to 200 mg and the cell number of TAMs collected ranged from 5 × 10^5^to 1 × 10^7^per 100 mg tumor tissue.

TAMs from lung cancer tissue had an irregular shape and projections (Figure [1A](#F1){ref-type="fig"}). To confirm that the cell isolated from the lung cancer tissue were TAMs without contamination by fibroblasts or tumor cells, staining for the macrophage specific marker *CD68*was performed. Over ninety-five percent of the cells stained positively for each randomly selected patient (Figure [1B](#F1){ref-type="fig"}).

![**Characterization of tumor-associated macrophage**. A. Representative cell morphology of tumor-associated macrophages, TAM, fibroblast and lung tumor cell. B. Immunofluorescent was used to distinguish macrophage, fibroblast and lung tumor cell with antibodies targeting *CD68*(red), nuclei stained with DAPI (blue). Original magnification, × 400.](1756-9966-30-62-1){#F1}

The mRNA expression levels of *IL-10, cathepsin B*and *cathepsin S*in normal macrophages
----------------------------------------------------------------------------------------

We performed a time course study to show the expression level of *IL-10*, *cathepsin B*and *cathepsin S*in monocytes changes after culture in medium with rhM-CSF. Our study showed the expression level of IL-10, cathepsin B and cathepsin S showed no significant changes in the time dependent study. (All p \> 0.05) (Figure [2A](#F2){ref-type="fig"}). We also performed dose depedent study of rhM-CSF to see whether the expression level of IL-10, cathepsin B and cathepsin S were affected or not. Our study showed that the dose of rhM-CSF did not affect the expression level of IL-10, cathepsin B and cathepsin S (Figure [2B](#F2){ref-type="fig"}).

![**The mRNA expression levels of IL-10, cathepsin B and cathepsin S in normal macrophages**. Results are given as fold increase in mRNA expression with respect to expression in D0 monocytes. Data were normalized to expression of the β-actin gene. A: Monocytes(D0) was used as a calibrator. B, monocytes culture without rhM-CSF was used as a calibrator (Ctrl). Error bar is SD, Independent experiments were repeated three times, all \#p \> 0.05(by student t-test).](1756-9966-30-62-2){#F2}

The mRNA expression levels of *IL-10, cathepsin B*and *cathepsin S*in TAMs
--------------------------------------------------------------------------

The mRNA expression levels of *IL-10, cathepsin B*and *cathepsin S*in TAMs were analyzed using QRT-PCR, compared with matched normal macrophages from the 63 patients. To explore the best time point for analyzing the expression level of *IL-10, cathepsin B*and *cathepsin S*, a time course study was done. After adhere to plastic for 20 min, 40 min, 60 min and 90 min, the expression level of IL-10 were: 28.3 ± 2.3; 28.1 ± 1.1; 24.6 ± 2.1; 14.7 ± 2.9 respectively, and the purity of TAMs were: 100%, 97%, 95%, 84% respectively (staining for the macrophage specific marker *CD68*was performed). After 60 min, tumor cells and fibroblast began to adhere, the purity decreased rapidly. So we chose 40 min as the time point for adherence, which is consistent with previous reports \[[@B23]\] (Figure [3](#F3){ref-type="fig"}).

![**The mRNA expression levels of *IL-10, cathepsin B*and *cathepsin S*in TAM changes in primary culture**. Results are given as fold increase in mRNA expression with respect to expression in ctrl (normal macrophages). Data were normalized to expression of the *β-actin*gene. Normal macrophages were used as a calibrator. Error bar is SD; Independent experiments were repeated three times.](1756-9966-30-62-3){#F3}

Compared with the expression in macrophage, *IL-10*and *cathepsin B*were significantly upregulated (p \< 0.05). After normalized to macrophages, the median values (range) of each gene in TAM were: *IL-10*, 30.5(0.6-530.3) and *cathepsin B*, 11.9(0.6-69.1) (Figure [4 A-B](#F4){ref-type="fig"}). There were no significant differences in the level of *cathepsin S*between the TAMs(0.85(0.04-4.49))and the macrophages (Figure [4C](#F4){ref-type="fig"}).

![**mRNA from TAMs and matched normal macrophage(Mφ) was analyzed by Quantitative real-time RT-PCR for expression of the indicated genes in 63 NSCLC samples**. Results are given as fold increase in mRNA expression with respect to expression in matched Mφ. Data were normalized to expression of the β-actin gene. Mφ was used as a calibrator. Bars represent median. *\*p*by the Mann-Whitney U test.](1756-9966-30-62-4){#F4}

Immunohistochemistry
--------------------

To confirm whether TAMs express *IL-10*and *cathepsin B*in protein level, 6 NSCLC (3 late stage (ⅢA) and 3 early stage (Ia- Ib)) were randomly selected to perform IHC using antibody against *CD68*, *IL-10*and *cathepsin B*on serial sections. We demonstrated that almost all *CD68*positive cells co-expressing *IL-10*, which in line with the QRT-PCR results that the IL-10 mRNA expression level is high (Figure [5 A-B](#F5){ref-type="fig"}). The *IL-10*expression was negative by IHC in 3 early stage NSCLC, which in line with the QRT-PCR results that the *IL-10*mRNA expression level below the median (30.5) in 3 early stage NSCLC. Expression of cathepsin B in macrophage was observed in 5 of 6 cases. Among macrophages expressing *cathepsin B*, only a small portion of the cells showed strong positive (Figure [5 C-D](#F5){ref-type="fig"}) and not associated with stage of disease.

![**Immunohistochemical expression of *IL-10*, *cathepsin B*and *CD68*in macrophage**. A-B, High IL-10 expression in macrophage, A, *IL-10*staining in macrophage (strong positivity); B, *CD68*staining. C-D, *Cathepsin B*expression in macrophage; C, *cathepsin B*staining in macrophage (most cells were moderate positivity, only a few cells were strong staining); D, *CD68*staining. Scale bar indicates 50 μm. Original magnification, × 400.](1756-9966-30-62-5){#F5}

The correlation between *IL-10, cathepsin B*expression in TAM and clinicopathologic factors
-------------------------------------------------------------------------------------------

The correlation between *IL-10, cathepsin B*expression in TAM and clinicopathologic factors was shown in Table [2](#T2){ref-type="table"}. A strongly positive correlation between *IL-10*mRNA expression in TAM and tumor stage was seen. Increased expression levels of *IL-10*in TAM were seen in NSCLC patients with late stage (stage II, III and IV). When multivariate logistic regression analysis was performed, *IL-10*expression in TAMs was shown to be an independent predictive factor for late stage disease (Table [3](#T3){ref-type="table"}).

###### 

Genes expression of TAM in relationship with clinicopathological factors

                                  *IL-10*             *Cathepsin B*                    
  -------------------------- ---- ------------------- --------------- ---------------- -------
  age                                                                                  
   \<58                      26   31.3(3.05-530.3)    0.252           10.9(0.9-51.9)   0.41
   ≥58                       37   30.5(0.6-511.6)                     14.5(0.6-69.1)   
  Gender                                                                               
   Male                      40   31.3(1.3-530.3)     0.607           14.9(0.9-69.1)   0.061
   Female                    23   19.9(0.6-426.1)                     10.1(0.6-37.9)   
  Smoking history                                                                      
   Never                     29   30.5(0.6-426.1)     0.699           10.1(0.6-51.9)   0.067
   Former or current         34   31.2(1.3-530.3)                     14.9(1.5-69.1)   
  Histology                                                                            
   Adenocarcinoma            34   42.9(0.6-530.3)     0.045           12.7(0.6-69.1)   0.41
   Squamous cell carcinoma   20   17.1(1.3-354.3)                     16.6(1.5-41.7)   
   Others                    9    41.2(6.4-511.6)                     10.2(4.2-26.7)   
  Pathological stage                                                                   
   Stage I                   30   9.7(0.6-140.8)      0.016           13.1(0.6-69.1)   0.066
   StageⅡ                    11   28.9(1.8-511.6)                     13.6(3.1-41.7)   
   StageⅢ                    17   177.7(23.5-530.3)                   11.8(1.2-51.9)   
   StageⅣ                    5    249.9(55.4-429.9)                   10.1(3.6-25.9)   
  T status                                                                             
   T1                        15   4.1(0.6-263.6)      \<0.0001        9.9(0.6-22.7)    0.037
   T2-3                      48   42.9(1.6-530.3)                     14.2(0.9-69.1)   
  Lymph node metastasis                                                                
   N(+)                      21   119.1(6.1-530.3)    \<0.0001        13.6(1.2-46.9)   0.466
   N(-)                      42   19.2(0.6-273.8)                     11.1(0.6-69.1)   
  Lymphovascular invasion                                                              
   LVI(+)                    12   93.1(6.2-530.3)     0.01            14.2(0.9-37.8)   0.92
   LVI(-)                    51   26.5(0.6-429.9)                     11.1(0.6-69.1)   
  Pleural invasion                                                                     
   PL(+)                     20   55.8(14.9-530.3)    0.002           14.2(0.9-69.1)   0.376
   PL(-)                     43   19.9(0.6-354.9)                     11.1(0.6-51.9)   
  Differentiation                                                                      
   Well or Moderately        30   17.3(0.6-429.9)     0.001           13.0(0.6-69.1)   0.961
   poorly                    26   113.1(1.6-530.3)                    11.9(1.2-37.9)   

*\*p*by the Mann-Whitney U test

###### 

Logistic regression analysis of the association between tumor stage and clinicopathological features (n = 63)

                                            B        SEM     Chi-squared   p-value   OR (95% CI)
  ----------------------------------------- -------- ------- ------------- --------- ----------------------
  **Sex**                                   0.241    1.110   0.037         0.847     1.239(0.141-10.922)
  **Age**                                   -0.063   0.040   2.484         0.115     0.939(0.868-1.015)
  **Tobacco use**                           1.173    1.102   1.133         0.287     3.231(0.373-28.005)
  **Histology**                             0.292    0.531   0.303         0.582     1.339(0.473-3.793)
  **High level *IL-10*expression in TAM**   2.952    0.742   15.844        0.0001    19.137(4.474-81.859)

The dependent variabl**e is**early- or late-stage group The independent variables included sex (0 = female; 1 = male), age (continuous variable, in yrs), Tobacco use (0 = Current,1 = Former,2 = Never), histology (1 = adenocarcinoma; 2 = squamous cell carcinoma;3 = others) and IL-10 expression (0 = low (\<30.5); 1 = high (≥30.5). OR: odds ratio; CI: confidence interval.

The increased mRNA expression of *IL-10*was also associated with lymph node metastasis, lymphovascular invasion, pleural invasion and poor differentiation (p \< 0.0001, p = 0.010, p = 0.017 p = 0.001, respectively).

A correlation between *cathepsin B*mRNA expression in TAM with NSCLC tumor T status was found (p = 0.037). Otherwise, there was no significant relationship between the mRNA expression of *cathepsin B*with any other clinicopathological factors (all p \> 0.05).

Discussion
==========

Increased infiltration of TAMs into NSCLC correlates with a poor prognosis \[[@B5],[@B9]\]. However, the mechanisms for this effect remain unclear. TAM derived molecules that function to suppress immune activation, promote extracellular matrix (ECM) remodeling may play important roles in NSCLC progression.

In the present study, the rational we selected *IL-10, cathepsin B*or *cathepsin S*, is that they were reported to be closely associated with TAMs in recent literatures \[[@B10]-[@B12],[@B24]\]. *IL-10*is widely known as an potent immunosuppressive cytokine associated with cancer \[[@B13],[@B25]\]. It is produced by a number of cells, including tumor cells and TAMs\[[@B14],[@B25]\]. *Cathepsins B, cathepsin S*, proteolytic enzymes, were thought to facilitate the breakdown of basement membranes thereby promoting cancer cell invasion into surrounding normal tissues. TAM expressed *cathepsin B*or *cathepsin S*in pancreatic islet, breast or prostate cancer animal models. In our study, we showed, TAM expressed high levels of *IL-10, cathepsin B*, but not *cathepsin S*in NSCLC.

Our study suggested that increased *IL-10*expression of TAM in NSCLC patients correlated with late stage disease (stage II, III and IV), lymph node metastases, pleural invasion, lymphovascular invasion and poor differentiation. Although recent animal model studies indicated that *cathepsin B*or *cathepsin S*expressed by TAM play an important role in tumor progression\[[@B10],[@B11]\], and we also found *cathepsin B*upregulated in TAM, we failed to demonstrate any correlation between *cathepsin B*in TAM and stage, lymph nodal metastasis, pleural invasion or differentiation in NSCLC.

TAMs are derived from blood monocytes that are attracted to a tumor by cytokines and chemokines\[[@B14]\]. In the tumor microenvironment, monocytes differentiate into a distinct macrophage phenotype, which is characterized by the production of high level of *IL-10*. TAM with high *IL-10*expression level may tune inflammatory responses and adaptive Th2 immunity, exhibit anti-inflammatory and tissue remodeling functions and thereby, to favor tumor progression\[[@B14]\]. We demonstrated that NSCLC patients with late stage disease had a higher level of *IL-10*expression in TAM, which further supports this hypothesis.

*IL-10*is a potent immunosuppressive factor that may promote lung cancer growth by suppressing macrophage function and enabling tumors to evade immunosurveillance\[[@B26]\]. The potential importance of *IL-10*in cancer progression is supported by reports of an association between high *IL-10*levels in serum or in tumors and worse survival in lung cancer patients\[[@B15]\]. However, other authors demonstrated that lack of *IL-10*expression by the tumor was associated with a worse survival in patients with stage I NSCLC \[[@B16]\]. The reason for these conflicting results might be that, both tumor cells and stromal(including macrophage) cells can secrete *IL-10*. Additionally, Wagner S et al identified that macrophage was the major source of *IL-10*in gliomas\[[@B27]\]. So it is important to isolate TAM from tumor cells to study the role of *IL-10*in the progression of cancer. In our study, we demonstrated the phenotype of isolated TAM was closely associated with clinicopathological features. We can predict tumor size, lymph nodal metastasis and pleural invasion through.*IL-10*expression in isolated TAM. We also found that the high expression of *IL-10*in TAM was associated with poorly differentiation, which highlighted a significance role of *IL-10*secreted by TAM in tumor aggressiveness.

A crucial step of cancer invasion and metastasis is the destruction of basement membrane by proteases. Recent studies showed invasion of cancer cell is increased by the proteases secreted from TAMs. *Cathepsin B*or *cathepsin S*has been implicated in the progression of various human cancers, including bladder, breast, prostate and lung cancers \[[@B17],[@B28]-[@B30]\]. The cellular source of this protease in human cancers, consisting of both tumor cells and stromal cells (e.g., fibroblasts, endothelial cells, and TAMs), has remained elusive. Studies using animal models have demonstrated that TAMs are the primary source of high levels of *cathepsin B*or *cathepsin S*in prostate, pancreatic islet cancers, and mammary tumors, and its expression by TAMs plays critical roles in multiple stages of tumor growth and metastasis\[[@B10],[@B12],[@B29]\]. Our studies demonstrated that TAM isolated from NSCLC overexpressed *cathepsin B*but not *cathepsin S*, and the *cathepsin B*levels were not associated with NSCLC stage, lymph metastasis, lymphovascular invasion or histological differentiation.

Conclusions
===========

*Interleukin-10*expression in tumor-associated macrophages correlates with disease aggressiveness of non-small cell lung cancer. We plan to conduct further studies to analyze the relationship between *IL-10*in TAM and survival. The study concerning regulation of *IL-10*in TAM is ongoing too. It will help to clarify and understand the possible mechanisms *IL-10*secreted by TAM in the progression of NSCLC.
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